Announcements
CuraAX Designed to Treat Neurogenic Orthostatic Hypotension (nOH) and Cognitive Impairment Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has treated its first subject with CuraAX, an alpha-1A adrenoceptor agonist, in…
Read More
Excerpt from the Press Release: SAN DIEGO, Feb. 19, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of peluntamig (PT217) in combination with chemotherapy. Peluntamig (PT217), a first-in-class native…
Read More
In the complex world of pharmaceutical clinical trials, efficiency, accuracy, and real-time data access are paramount. Systems integration plays a crucial role in ensuring these elements are met, significantly improving the trial process. By integrating multiple technology systems-such as Electronic Data Capture (EDC), clinical trial management systems (CTMS), and imaging platforms-trial teams can create a…
Read More
Excerpt from the Press Release: BOSTON & SHENZHEN, China–(BUSINESS WIRE)–Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SIGX1094, the world’s first potential targeted therapy for diffuse gastric cancer (DGC). This designation is designed to accelerate…
Read More
PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b as a monotherapy in RSK2-high metastatic breast cancer patients. Excerpt from the Press Release: SAN DIEGO and VANCOUVER, British Columbia, Feb. 20, 2025 (GLOBE NEWSWIRE) — Phoenix Molecular Designs (PhoenixMD), a female-founded clinical-stage precision oncology company focused on developing precise cancer therapeutics,…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of…
Read More Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of…
Read More Excerpt from the Press Release: SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured in an interview with Alpha Wolf Trading. In the discussion,…
Read More Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 14, 2025– Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)…
Read More Excerpt from the Press Release: NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers…
Read More